

Title (en)

METHOD FOR IDENTIFYING AND/OR FOR OBTAINING AN ACTIVE SUBSTANCE FOR THE TREATMENT AND THERAPY OF FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS, AND USE OF AN ACTIVE SUBSTANCE FOR THE TREATMENT OF THIS DISEASE

Title (de)

VERFAHREN ZUR IDENTIFIZIERUNG UND/ODER ZUM ERHALTEN EINES WIRKSTOFFS ZUR BEHANDLUNG UND THERAPIE DER FAMILIÄREN AMYOTROPHEN LATERALSKLEROSE SOWIE VERWENDUNG EINES WIRKSTOFFS ZUR BEHANDLUNG DIESER ERKRANKUNG

Title (fr)

MÉTHODE POUR L'IDENTIFICATION ET/OU L'OBTENTION D'UN PRINCIPE ACTIF POUR LE TRAITEMENT ET LA THÉRAPIE DE LA FORME FAMILIALE DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE ET UTILISATION D'UN PRINCIPE ACTIF POUR LE TRAITEMENT DE CETTE MALADIE

Publication

**EP 4264262 A2 20231025 (DE)**

Application

**EP 21819718 A 20211105**

Priority

- DE 102020007691 A 20201216
- DE 2021000183 W 20211105

Abstract (en)

[origin: WO2022127956A2] The invention relates to a method for identifying and/or obtaining active substances for the alleviation or treatment of ALS, comprising the following steps: a. providing a composition containing cells having the cell surface receptors syndecan-3 and/or syndecan-1, b. contacting the composition from step a) with SOD1 aggregates, c. contacting the composition from step a) with the test substance to be screened, it being possible for step b) and step c) to be performed simultaneously or for step c) to be performed before step b), d. determining the uptake of the SOD1 aggregates into the cells. The invention moreover relates to a kit or a composition for conducting the method according to the invention, containing at least cells expressing the cell surface receptors syndecan-3 and/or syndecan-1 and also SOD1 aggregates. The invention further relates to pentosan polysulfate sodium (PPS) or compounds from the group of the heparins or heparin-like compounds, for use in the preparation of an inhibitor for the uptake of SOD1 aggregates in neurons or neuronal cells of an organism and as medicament in the treatment of ALS.

IPC 8 full level

**G01N 33/50** (2006.01); **A61K 31/737** (2006.01)

CPC (source: EP US)

**A61K 31/727** (2013.01 - EP US); **A61K 31/737** (2013.01 - US); **A61P 25/28** (2017.12 - US); **G01N 33/5008** (2013.01 - EP); **G01N 33/5038** (2013.01 - US); **G01N 33/5058** (2013.01 - EP US); **G01N 2800/28** (2013.01 - EP)

Citation (search report)

See references of WO 2022127956A2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

**WO 2022127956 A2 20220623**; **WO 2022127956 A3 20220811**; DE 102020007691 A1 20220623; EP 4264262 A2 20231025; US 2024033282 A1 20240201

DOCDB simple family (application)

**DE 2021000183 W 20211105**; DE 102020007691 A 20201216; EP 21819718 A 20211105; US 202118256926 A 20211105